U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07050043) titled 'Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC' on May 15.
Brief Summary: This is a multicenter, two-arm randomized, parallel group design trial to evaluate superiority and safety of low dose Nivolumab (40mg) combined with standard chemotherapy versus standard chemotherapy alone in patients with non-small cell lung cancer.
Study Start Date: May 19
Study Type: INTERVENTIONAL
Condition:
NSCLC (Non-small Cell Lung Carcinoma)
First Line Therapy
Locally Advanced/Metastatic NSCLC
Intervention:
DRUG: Nivolumab 40mg
Nivolumab is an immunotherapy medicine used to tr...